For non-ST elevation acute coronary syndrome (NSTE-ACS). ANDA 216379, held by Eugia Pharma. Tirofiban Hydrochloride.
As of Nov 16, 2026, ANDA 216379 (Tirofiban Hydrochloride), held by Eugia Pharma, was first approved by FDA on May 1, 2023, with 0 approved supplements and 0 published complete response letters.
Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 1, 2023 | Original application | Approved | None posted |
| Tirofiban HydrochlorideEQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) · solution;intravenous | Tirofiban Hydrochloride | Rx |
| Tirofiban HydrochlorideEQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) · solution;intravenous | Tirofiban Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters